Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 7 Pheochromocytoma 2 Paraganglioma 2 Gastro-enteropancreatic neuroendocrine tumor 2 Vipoma 1 Thymus Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Meningioma 1 Insulinoma 1 Gastrinoma 1 Carcinoma, Merkel Cell 1 Carcinoid Tumor 1

Interventions

Magnetic Resonance Spectroscopy 12 gallium Ga 68 dotatate 6 Everolimus 6 lutetium Lu 177 dotatate 5 Radiosurgery 5 Proton Therapy 5 Bevacizumab 5 pembrolizumab 4 Surveys and Questionnaires 4 Specimen Handling 4 Hydroxyurea 4 abemaciclib 3 Tranexamic Acid 3 Surgical Procedures, Operative 3 Sodium Chloride 3 Ga(III)-DOTATOC 3 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3 vistusertib 2 trametinib 2 ribociclib 2 arginyllysine 2 aldesleukin 2 Yoga 2 Whole Body Imaging 2 Sunitinib 2 Saline Solution 2 Ropivacaine 2 Radiotherapy 2 Protons 2 Observation 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Meningioma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all

NCT04997317 2025-04-13

PROMENADE

University Hospital, Basel, Switzerland

Phase 1/2 Recruiting

Meningioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡